195 related articles for article (PubMed ID: 38437557)
1. Targeting and monitoring ovarian cancer invasion with an RNAi and peptide delivery system.
Hao L; Boehnke N; Elledge SK; Harzallah NS; Zhao RT; Cai E; Feng YX; Neaher S; Fleming HE; Gupta PB; Hammond PT; Bhatia SN
Proc Natl Acad Sci U S A; 2024 Mar; 121(11):e2307802121. PubMed ID: 38437557
[TBL] [Abstract][Full Text] [Related]
2. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
3. Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer.
Hong SS; Zhang MX; Zhang M; Yu Y; Chen J; Zhang XY; Xu CJ
Drug Deliv; 2018 Nov; 25(1):576-584. PubMed ID: 29461120
[TBL] [Abstract][Full Text] [Related]
4. Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells.
Palanca-Wessels MC; Booth GC; Convertine AJ; Lundy BB; Berguig GY; Press MF; Stayton PS; Press OW
Oncotarget; 2016 Feb; 7(8):9561-75. PubMed ID: 26840082
[TBL] [Abstract][Full Text] [Related]
5. Theranostic Layer-by-Layer Nanoparticles for Simultaneous Tumor Detection and Gene Silencing.
Boehnke N; Correa S; Hao L; Wang W; Straehla JP; Bhatia SN; Hammond PT
Angew Chem Int Ed Engl; 2020 Feb; 59(7):2776-2783. PubMed ID: 31747099
[TBL] [Abstract][Full Text] [Related]
6. Blocking Stemness and Metastatic Properties of Ovarian Cancer Cells by Targeting p70
Ma J; Kala S; Yung S; Chan TM; Cao Y; Jiang Y; Liu X; Giorgio S; Peng L; Wong AST
Mol Ther; 2018 Jan; 26(1):70-83. PubMed ID: 29241971
[TBL] [Abstract][Full Text] [Related]
7. SMARCE1 is required for the invasive progression of in situ cancers.
Sokol ES; Feng YX; Jin DX; Tizabi MD; Miller DH; Cohen MA; Sanduja S; Reinhardt F; Pandey J; Superville DA; Jaenisch R; Gupta PB
Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4153-4158. PubMed ID: 28377514
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer.
Giannakakis A; Karapetsas A; Dangaj D; Lanitis E; Tanyi J; Coukos G; Sandaltzopoulos R
Int J Biochem Cell Biol; 2014 Aug; 53():389-98. PubMed ID: 24880093
[TBL] [Abstract][Full Text] [Related]
9. siRNA delivery for the treatment of ovarian cancer.
Goldberg MS
Methods; 2013 Sep; 63(2):95-100. PubMed ID: 23403216
[TBL] [Abstract][Full Text] [Related]
10. Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines.
Numnum TM; Makhija S; Lu B; Wang M; Rivera A; Stoff-Khalili M; Alvarez RD; Zhu ZB; Curiel DT
Gynecol Oncol; 2008 Jan; 108(1):34-41. PubMed ID: 18061250
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.
Chakravarty D; Roy SS; Babu CR; Dandamudi R; Curiel TJ; Vivas-Mejia P; Lopez-Berestein G; Sood AK; Vadlamudi RK
Clin Cancer Res; 2011 Apr; 17(8):2250-9. PubMed ID: 21421858
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N
Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405
[TBL] [Abstract][Full Text] [Related]
13. Expression of BAF57 in ovarian cancer cells and drug sensitivity.
Yamaguchi T; Kurita T; Nishio K; Tsukada J; Hachisuga T; Morimoto Y; Iwai Y; Izumi H
Cancer Sci; 2015 Apr; 106(4):359-66. PubMed ID: 25611552
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide-siRNA Nanocomplexes.
Lo JH; Kwon EJ; Zhang AQ; Singhal P; Bhatia SN
Bioconjug Chem; 2016 Oct; 27(10):2323-2331. PubMed ID: 27583545
[TBL] [Abstract][Full Text] [Related]
15. Peptide/Lipid-Associated Nucleic Acids (PLANAs) as a Multicomponent siRNA Delivery System.
Hall R; Alasmari A; Mozaffari S; Mahdipoor P; Parang K; Montazeri Aliabadi H
Mol Pharm; 2021 Mar; 18(3):986-1002. PubMed ID: 33496597
[TBL] [Abstract][Full Text] [Related]
16. In vivo application of RNA interference: from functional genomics to therapeutics.
Lu PY; Xie F; Woodle MC
Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
[TBL] [Abstract][Full Text] [Related]
17. Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy.
Chen Y; Wang X; Liu T; Zhang DS; Wang Y; Gu H; Di W
Int J Nanomedicine; 2015; 10():2579-94. PubMed ID: 25848273
[TBL] [Abstract][Full Text] [Related]
18. Advances in RNAi therapies for gastric cancer: Targeting drug resistance and nanoscale delivery.
Hashemi M; Aparviz R; Beickzade M; Paskeh MDA; Kheirabad SK; Koohpar ZK; Moravej A; Dehghani H; Saebfar H; Zandieh MA; Salimimoghadam S; Rashidi M; Taheriazam A; Entezari M; Samarghandian S
Biomed Pharmacother; 2023 Dec; 169():115927. PubMed ID: 38006616
[TBL] [Abstract][Full Text] [Related]
19. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
